KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EBITDA: 2009-2024

Historic EBITDA for Novavax (NVAX) over the last 16 years, with Dec 2024 value amounting to -$248.9 million.

  • Novavax's EBITDA fell 32.83% to -$178.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.5 million, marking a year-over-year increase of 202.01%. This contributed to the annual value of -$248.9 million for FY2024, which is 56.06% up from last year.
  • Latest data reveals that Novavax reported EBITDA of -$248.9 million as of FY2024, which was up 56.06% from -$566.5 million recorded in FY2023.
  • Novavax's 5-year EBITDA high stood at -$248.9 million for FY2024, and its period low was -$1.7 billion during FY2021.
  • Over the past 3 years, Novavax's median EBITDA value was -$566.5 million (recorded in 2023), while the average stood at -$486.7 million.
  • As far as peak fluctuations go, Novavax's EBITDA crashed by 304.73% in 2021, and later skyrocketed by 61.77% in 2022.
  • Over the past 5 years, Novavax's EBITDA (Yearly) stood at -$416.7 million in 2020, then tumbled by 304.73% to -$1.7 billion in 2021, then spiked by 61.77% to -$644.7 million in 2022, then grew by 12.13% to -$566.5 million in 2023, then spiked by 56.06% to -$248.9 million in 2024.